Treatment-related benefit and satisfaction in patients with Fabry disease in France: insight into patients' expectations and preferences from the prospective, non-interventional SATIS-Fab study - PubM
19 hours ago
- #Patient benefit
- #Fabry disease
- #Treatment satisfaction
- The SATIS-Fab study evaluated treatment-related benefit and satisfaction in Fabry disease patients in France over 2 years.
- Most patients were prescribed migalastat, with stable high treatment benefit reported via the Patient Benefit Index (PBI).
- Switching from enzyme replacement therapy (ERT) to migalastat significantly increased treatment benefit and satisfaction scores.